                </a></li></ul></div><p><strong>Figure 7.  <span>Polycythemia and reticulocytosis induced by JAK2 V617F responds to kinase inhibitor therapy.</span></strong></p><a id="article1.body1.sec3.sec7.fig1.caption1.p1" name="article1.body1.sec3.sec7.fig1.caption1.p1"></a><p>(A) Hematocrit (left panel) and reticulocyte counts (right panel) of cohorts of mice treated with twice daily oral gavage with 100 mg/kg imatinib (<em>n</em> = 3), 10 mg/kg dasatinib (<em>n</em> = 4), or vehicle (<em>n</em> = 2), determined before initiation of therapy (white bars, “pre”) or after 2 weeks of treatment (black bars, “post”).</p>
<a id="article1.body1.sec3.sec7.fig1.caption1.p2" name="article1.body1.sec3.sec7.fig1.caption1.p2"></a><p>The hematocrit and reticulocyte count were significantly decreased in response to imatinib therapy (<em>P</em> = 0.0267 and <em>P</em> = 0.0053, respectively, unpaired <em>t</em>-test), while imatinib had no effect on these parameters in normal mice (data not shown).</p>
<a id="article1.body1.sec3.sec7.fig1.caption1.p3" name="article1.body1.sec3.sec7.fig1.caption1.p3"></a><p>(B) Inhibition of Ba/F3 parental cells grown in IL-3 (green squares) or Ba/F3 cells expressing BCR-ABL (magenta triangles) or JAK2 V617F (red circles) grown without IL-3 by JAK Inhibitor I (left) or AG-490 (right).</p>
<a id="article1.body1.sec3.sec7.fig1.caption1.p4" name="article1.body1.sec3.sec7.fig1.caption1.p4"></a><p>Note that both JAK Inhibitor I and AG-490 inhibit IL-3-dependent proliferation of parental Ba/F3 cells, but only AG-490 inhibits the growth of BCR-ABL-expressing cells, as previously reported <a href="#pone.0000018-Xie1">[48]</a>.</p>
<a id="article1.body1.sec3.sec7.fig1.caption1.p5" name="article1.body1.sec3.sec7.fig1.caption1.p5"></a><p>(C) Hematocrit (left panel) and reticulocyte counts (right panel) of mice treated with continuous parenteral administration of 300 µg/day AG-490 (<em>n</em> = 3) or vehicle (<em>n</em> = 2), determined before initiation of therapy (white bars), or after 2 weeks of treatment (black bars).</p>
<a id="article1.body1.sec3.sec7.fig1.caption1.p6" name="article1.body1.sec3.sec7.fig1.caption1.p6"></a><p>The hematocrit and reticulocyte count were significantly decreased in response to AG-490 therapy (<em>P</em> = 0.0134 and <em>P</em> = 0.0374, respectively, unpaired <em>t</em>-test).</p>
<a id="article1.body1.sec3.sec7.fig1.caption1.p7" name="article1.body1.sec3.sec7.fig1.caption1.p7"></a><p>There was no significant effect of AG-490 on the hematocrit or reticulocyte count of recipients of JAK2 WT-transduced BM (data not shown).</p>
<span>THISISTHEEND
